The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus

Ayşe Anık; Elif Çelik; Özge Çevik; Tolga Ünüvar; Ahmet Anık

doi:10.1515/jpem-2020-0146

Article

The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus

Ayşe Anık , Elif Çelik , Özge Çevik , Tolga Ünüvar and Ahmet Anık

Published/Copyright: July 23, 2020

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Pediatric Endocrinology and Metabolism Volume 33 Issue 8

Abstract

Objectives

Endothelial dysfunction is an early marker of vascular disease in Type 1 diabetes mellitus (T1DM). In the present study, we aimed to investigate serum endocan and soluble endoglin (S-endoglin) levels, and their relation with metabolic control in children with T1DM, which was not previously assessed.

Methods

A total of 64 T1DM subjects and 64 healthy subjects were included in this study. Their anthropometric features, arterial blood pressures, pubertal status, insulin doses were recorded. Glycated hemoglobin, serum endocan and S-endoglin levels were measured and compared to each other.

Results

Serum endocan and S-endoglin levels were higher in children with T1DM than those of healthy group (p<0.01). Significant positive correlation was detected between both endocan and S-endoglin (r=0.579, p<0.001); and HbA1c and endocan (r=0.296, p=0.01). Compared to patients with good metabolic control, those with poorer metabolic control (HbA1c > 8%) had an older age, longer duration of diabetes, higher number of pubertal children. Also, patients with poorer metabolic control had higher endocan and S-endoglin levels than those of healthy group, but this finding did not reach statistical significance. There was no correlation between the endocan/S-endoglin levels and age, duration of diabetes and insulin dose.

Conclusion

Serum levels of endocan and S-endoglin which are novel biomarkers of endothelial dysfunction are high in children with T1DM. Elevated serum endocan and endoglin levels in children with T1DM without microvascular complications indicates endothelial damage in very early stages of the disease.

Keywords: endocrinology; endocan; endoglin; endothelium; pediatric endocrinology; type 1 diabetes

Corresponding author: Ahmet Anik, Ass. Prof., Department of Pediatric Endocrinology, Faculty of Medicine, Aydın Adnan Menderes University, 09100, Aydın, Turkey, Phone: +902562145400, E-mail: ahmet.anik@yahoo.com

Funding source: Aydin Adnan Menderes University

Award Identifier / Grant number: TPF-19046

Research funding: This study has been supported by Aydin Adnan Menderes University Research Grant (TPF-19046).
Author contributions: All authors designed the study, analyzed the data, contributed to the manuscript, accepted responsibility for the entire content of this submitted manuscript and approved submission.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Ethical approval: This study was approved by the Ethics Committee of the Aydın Adnan Menderes University.

References

1. Schnell, O, Cappuccio, F, Genovese, S, Standl, E, Valensi, P, Ceriello, A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol 2013;12:156. https://doi.org/10.1186/1475-2840-12-156.Search in Google Scholar

2. Zhang, Y, Zhang, H, Li, P. Cardiovascular risk factors in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2019;32:699–705. https://doi.org/10.1515/jpem-2018-0382.Search in Google Scholar

3. Gourgari, E, Dabelea, D, Rother, K. Modifiable risk factors for cardiovascular disease in children with type 1 diabetes: can early intervention prevent future cardiovascular events? Curr Diab Rep 2017;17:134. https://doi.org/10.1007/s11892-017-0968-y.Search in Google Scholar

4. Gimbrone, MAJr., Garcia-Cardena, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016;118:620–36. https://doi.org/10.1161/circresaha.115.306301.Search in Google Scholar

5. Jenkins, A, Januszewski, A, O’Neal, D. The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovasc Endocrinol Metab 2019;8:14–27. https://doi.org/10.1097/xce.0000000000000169.Search in Google Scholar

6. Pomilio, M, Mohn, A, Verrotti, A, Chiarelli, F. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:343–61. https://doi.org/10.1515/jpem.2002.15.4.343.Search in Google Scholar

7. Castro-Correia, C, Santos-Silva, R, Pinheiro, M, Costa, C, Fontoura, M. Metabolic risk factors in adolescent girls with type 1 diabetes. J Pediatr Endocrinol Metab 2018;31:631–5. https://doi.org/10.1515/jpem-2018-0053.Search in Google Scholar

8. Leite, AR, Borges-Canha, M, Cardoso, R, Neves, JS, Castro-Ferreira, R, Leite-Moreira, A. Novel biomarkers for evaluation of endothelial dysfunction. Angiology 2020;71:397–410. https://doi.org/10.1177/0003319720903586.Search in Google Scholar

9. Wang, XS, Yang, W, Luo, T, Wang, JM, Jing, YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015;19:124–7. https://doi.org/10.1089/gtmb.2014.0274.Search in Google Scholar

10. Balta, S, Mikhailidis, DP, Demirkol, S, Ozturk, C, Celik, T, Iyisoy, A. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015;243:339–43. https://doi.org/10.1016/j.atherosclerosis.2015.09.030.Search in Google Scholar

11. Icli, A, Cure, E, Cure, MC, Uslu, AU, Balta, S, Mikhailidis, DP, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology 2016;67:749–55. https://doi.org/10.1177/0003319715616240.Search in Google Scholar

12. Jang, YS, Choi, IH. Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw 2014;14:237–40. https://doi.org/10.4110/in.2014.14.5.237.Search in Google Scholar

13. Ekiz-Bilir, B, Bilir, B, Aydin, M, Soysal-Atile, N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Arch Med Sci 2019;15:86–91. https://doi.org/10.5114/aoms.2018.79488.Search in Google Scholar

14. American diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020;43(Suppl 1):S14–S31. https://doi.org/10.2337/dc20-S002.Search in Google Scholar

15. Neyzi, O, Bundak, R, Gokcay, G, Gunoz, H, Furman, A, Darendeliler, F, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015;7:280–93. https://doi.org/10.4274/jcrpe.2183.Search in Google Scholar

16. Tanner, JM, Whitehouse, RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–9. https://doi.org/10.1136/adc.51.3.170.Search in Google Scholar

17. Basu, S, Larsson, A, Vessby, J, Vessby, B, Berne, C. Type 1 diabetes is associated with increased cyclooxygenase–and cytokine-mediated inflammation. Diabetes Care 2005;28:1371–5. https://doi.org/10.2337/diacare.28.6.1371.Search in Google Scholar

18. Danesh, J, Whincup, P, Walker, M, Lennon, L, Thomson, A, Appleby, P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199–204. https://doi.org/10.1136/bmj.321.7255.199.Search in Google Scholar

19. Babar, GS, Zidan, H, Widlansky, ME, Das, E, Hoffmann, RG, Daoud, M, et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care 2011;34:681–5. https://doi.org/10.2337/dc10-2134.Search in Google Scholar

20. Balamir, I, Ates, I, Topcuoglu, C, Turhan, T. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology 2018;69:609–16. https://doi.org/10.1177/0003319717740781.Search in Google Scholar

21. Lv, Y, Zhang, Y, Shi, W, Liu, J, Li, Y, Zhou, Z, et al. The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci 2017;353:433–8. https://doi.org/10.1016/j.amjms.2017.02.004.Search in Google Scholar

22. Arman, Y, Akpinar, TS, Kose, M, Emet, S, Yuruyen, G, Akarsu, M, et al. Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology 2016;67:239–44. https://doi.org/10.1177/0003319715585664.Search in Google Scholar

23. Cikrikcioglu, MA, Erturk, Z, Kilic, E, Celik, K, Ekinci, I, Yasin Cetin, AI, et al. Endocan and albuminuria in type 2 diabetes mellitus. Ren Fail 2016;38:1647–53. https://doi.org/10.1080/0886022x.2016.1229966.Search in Google Scholar

24. Zhao, T, Kecheng, Y, Zhao, X, Hu, X, Zhu, J, Wang, Y, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Medicine (Baltimore) 2018;97:e13407. https://doi.org/10.1097/md.0000000000013407.Search in Google Scholar

25. Blann, AD, Wang, JM, Wilson, PB, Kumar, S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 1996;120:221–6. https://doi.org/10.1016/0021-9150(95)05713-7.Search in Google Scholar

26. Blazquez-Medela, AM, Garcia-Ortiz, L, Gomez-Marcos, MA, Recio-Rodriguez, JI, Sanchez-Rodriguez, A, Lopez-Novoa, JM, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010;8:86. https://doi.org/10.1186/1741-7015-8-86.Search in Google Scholar

27. Bilir, B, Ekiz Bilir, B, Yilmaz, I, Soysal Atile, N, Yildirim, T, Kara, SP, et al. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2016;20:892–8.Search in Google Scholar

28. Doghish, AS, Bassyouni, AA, Mahfouz, MH, Abd El-Aziz, HG, Zakaria, RY. Plasma endoglin in type 2 diabetic patients with nephropathy. Diabetes Metab Syndr 2019;13:764–8. https://doi.org/10.1016/j.dsx.2018.11.058.Search in Google Scholar

29. Emeksiz, HC, Bideci, A, Damar, C, Derinkuyu, B, Celik, N, Doger, E, et al. Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. J Clin Res Pediatr Endocrinol 2016;8:313–20. https://doi.org/10.4274/jcrpe.2906.Search in Google Scholar

30. Abu El-Asrar, AM, Nawaz, MI, De Hertogh, G, Al-Kharashi, AS, Van den Eynde, K, Mohammad, G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res 2015;40:321–31. https://doi.org/10.3109/02713683.2014.921312.Search in Google Scholar

Received: 2020-03-28

Accepted: 2020-05-06

Published Online: 2020-07-23

Published in Print: 2020-08-27

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jpem-2020-0146

Keywords for this article

endocrinology; endocan; endoglin; endothelium; pediatric endocrinology; type 1 diabetes